Johnson & Johnson


SKU: JNJ Category:


Johnson & Johnson has been in the news for a number of reasons off late. The company’s shareholders witnessed a small scare when the U.S. FDA hit a pause button on its Covid-19 vaccine due to concerns about rare blood clotting issues. However, this was eventually lifted though there continue to be concerns related to its vaccine with a recent Washington Post survey claiming that more than 75% of unvaccinated Americans would be hesitant to choose the company’s vaccine. Despite all these concerns, the management did not disappoint shareholders and delivered a strong result with increased revenue from the medical devices as well as its pharmaceutical segment. The Covid-19 vaccine also made a decent contribution to the top-line in the recent result and has a huge potential upside outside the U.S. in emerging markets like India.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $496 annual subscription!